Delving into the Latest Updates on RWJ-333442 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

MC 04699, MC-04,699, RWJ 333442

+ [1]

Target-

Mechanism

Cell wall inhibitors

Therapeutic Areas

Infectious Diseases

Active Indication

MRSA - Methicillin resistant Staphylococcus aureus infection

Inactive Indication-

Originator Organization

Essential Therapeutics, Inc.

Active Organization

Essential Therapeutics, Inc.

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Structure/Sequence

Molecular FormulaC23H25N9O8S4

InChIKeyIMDJAYYSHAOAPT-CCPHTHGOSA-N

CAS Registry331780-57-5

To improve the aqueous solubility of anti-methicillin-resistant Staphylococcus aureus cephalosporin RWJ-333441 for parenteral administration, acyl derivatives of the C-3 primary amino group were prepared and evaluated for solubility, cleavage in serum in vitro, and conversion to RWJ-333441 in vivo. Improved solubility at physiologic pH values and release of RWJ-333441 in vitro and in vivo were observed for several prodrugs, including the aspartate derivative RWJ-333442.

01 Feb 2001·Current opinion in investigational drugs (London, England : 2000)

RWJ-333441 Microcide/RW Johnson.

Review

Author: Jiraskova, N

Microcide and RW Johnson Pharmaceutical Research Institute are investigating a novel cephalosporin prodrug RWJ-333442 for the potential treatment of bacterial infections. RWJ-333442 is the prodrug of RWJ-333441; it has an improved solubility profile and studies are in progress in human serum, rats and rhesus macaques [382578], [382862], [383594].

100 Deals associated with RWJ-333442

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
MRSA - Methicillin resistant Staphylococcus aureus infection	Preclinical	US	Essential Therapeutics, Inc.	05 Mar 2003
Gram-Positive Bacterial Infections	Preclinical	US	Essential Therapeutics, Inc.	-